Case report: management of a 53-year-old postmenopausal women with an intact uterus who had been given unopposed oestrogen for 12 months

Maturitas ◽  
2015 ◽  
Vol 81 (1) ◽  
pp. 156-157
Author(s):  
Rachel Westwick
Keyword(s):  
Case Report ◽  
Postmenopausal Women ◽  
Intact Uterus ◽  
Unopposed Oestrogen

scholarly journals Breast miofibroblastoma in postmenopausal women: case report

2019 ◽  
Vol 10 (4) ◽  
Author(s):  
Victor E Valdespino ◽  
Israel Lopez Matamoros ◽  
Paola X Ferrer ◽  
Antonio Garcia Rodriguez ◽  
Claudia Meixueiro Calderon ◽  
...  
Keyword(s):  
Case Report ◽  
Postmenopausal Women

scholarly journals Spontaneous Postpartum Rupture of an Intact Uterus: A Case Report

2015 ◽  
Vol 7 (1) ◽  
pp. 56-58 ◽  
Author(s):  
George Mavromatidis ◽  
George Karavas ◽  
Chrysoula Margioula-Siarkou ◽  
Stamatios Petousis ◽  
Ioannis Kalogiannidis ◽  
...  
Keyword(s):  
Case Report ◽  
Intact Uterus

scholarly journals Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer

2015 ◽  
Vol 33 (10) ◽  
pp. 1186-1190 ◽  
Author(s):  
Polly A. Newcomb ◽  
Michael N. Passarelli ◽  
Amanda I. Phipps ◽  
Garnet L. Anderson ◽  
Jean Wactawski-Wende ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Treatment Of Osteoporosis ◽  
Endometrial Cancer Risk ◽  
Patients With Cancer ◽  
Oral Bisphosphonate ◽  
Intact Uterus ◽  
The Relationship

Purpose Bisphosphonates are common medications used for the treatment of osteoporosis and are also used to reduce metastases to bone in patients with cancer. Several studies, including the Women's Health Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies. This study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer. Methods We evaluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort of 89,918 postmenopausal women participating in the WHI. A detailed health interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of regularly used medications at baseline and over follow-up. All women had an intact uterus at the time of study entry. Results During a median follow-up of 12.5 years, 1,123 women were diagnosed with incident invasive endometrial cancer. Ever use of bisphosphonates was associated with reduced endometrial cancer risk (adjusted hazard ratio, 0.80; 95% CI, 0.64 to 1.00; P = .05), with no interactions observed with age, body mass index, or indication for use. Conclusion In this large prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically significant reduction in endometrial cancer risk.

scholarly journals Sertoli-Leydig cell tumor - a rare androgen secreting ovarian tumor in postmenopausal women: case report and review of literature

2003 ◽  
Vol 7 (4) ◽  
pp. 461-471 ◽  
Author(s):  
Ancuta Gheorghisan-Galateanu ◽  
Simona Fica ◽  
Dana Cristina Terzea ◽  
Andra Caragheorgheopol ◽  
V. Horhoianu
Keyword(s):  
Case Report ◽  
Postmenopausal Women ◽  
Leydig Cell ◽  
Ovarian Tumor ◽  
Leydig Cell Tumor ◽  
Cell Tumor ◽  
Review Of Literature

scholarly journals A postmenopausal women presenting with atypical symptoms and cervical cancer: a case report

Cases Journal ◽  
2008 ◽  
Vol 1 (1) ◽  
Author(s):  
Hooman Soleymani Majd ◽  
Sean Watermeyer ◽  
Essam El Hamamy ◽  
Lamiese Ismail
Keyword(s):  
Cervical Cancer ◽  
Case Report ◽  
Postmenopausal Women ◽  
Atypical Symptoms

scholarly journals A rare case of uterine leiomyosarcoma: A case report

2021 ◽  
Vol 8 (3) ◽  
pp. 404-407
Author(s):  
Bhuvana Preethi ◽  
Usha Rajesh ◽  
Mala Vijayakrishnan
Keyword(s):  
Smooth Muscle ◽  
Case Report ◽  
Smooth Muscle Cells ◽  
Postmenopausal Women ◽  
Malignant Tumor ◽  
Rare Case ◽  
Muscle Cells ◽  
Uterine Leiomyosarcoma ◽  
Postmenopausal Bleeding

Uterine leiomyosarcoma is a rare malignant tumor that arises from smooth muscle cells. It comprises of 1% of all uterine malignancy. We report a case of 54 year old Postmenopausal women with 2 episodes of postmenopausal bleeding and was diagnosed with Leiomyosarcoma of uterus.

Sign in / Sign up

Export Citation Format

Share Document